Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

A specific and robust immunoassay for the lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), platelet-activating factor acetylhydrolase, is described for the first time. The immunoassay was used to evaluate possible links between plasma Lp-PLA(2) levels and atherosclerosis risk amongst susceptib...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2000-06, Vol.150 (2), p.413-419
Main Authors: Caslake, M J, Packard, C J, Suckling, K E, Holmes, S D, Chamberlain, P, Macphee, C H
Format: Article
Language:English
Subjects:
1-Alkyl-2-acetylglycerophosphocholine Esterase
Adult
Aged
Antibodies, Monoclonal
Arteriosclerosis - diagnostic imaging
Arteriosclerosis - enzymology
Arteriosclerosis - etiology
Biomarkers - blood
Coronary Angiography
Enzyme-Linked Immunosorbent Assay
Humans
Lipids - blood
Male
Middle Aged
Phospholipases A - blood
Phospholipases A - immunology
Platelet Activating Factor - immunology
Platelet Activating Factor - metabolism
Platelet Activation
Prognosis
Risk Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A specific and robust immunoassay for the lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), platelet-activating factor acetylhydrolase, is described for the first time. The immunoassay was used to evaluate possible links between plasma Lp-PLA(2) levels and atherosclerosis risk amongst susceptible individuals. Such an investigation was important because Lp-PLA(2) participates in the oxidative modification of low density lipoprotein by cleaving oxidised phosphatidylcholines, generating lysophosphatidylcholine and oxidised free fatty acids. The majority of Lp-PLA(2) was found associated with LDL (approximately 80%) and, as expected, enzyme levels were significantly positively correlated to LDL cholesterol. Plasma Lp-PLA(2) levels were significantly elevated in patients with angiographically proven coronary artery disease (CAD) when compared with age-matched controls, even though LDL cholesterol levels did not differ significantly. Indeed, when included in a general linear model with LDL cholesterol and other risk factors, Lp-PLA(2) appeared to be an independent predictor of disease status. We propose, therefore, that plasma Lp-PLA(2) mass should be viewed as a potential novel risk factor for CAD that provides information related to but additional to traditional lipoprotein measurements.
ISSN:0021-9150
DOI:10.1016/S0021-9150(99)00406-2